Home-based treatment for patients with hematological cancer in Denmark–A national overview

TL;DR

This study explores how home-based treatments are used for blood cancer patients in Denmark and highlights variations in their implementation.

Contribution

The study provides a national overview of home-based treatment practices for hematological cancer patients in Denmark.

Findings

Six types of home-based therapies are used, including chemotherapy and immunoglobulin.

Most home treatments are given to multiple myeloma patients.

Variations exist in patient criteria and treatment initiation timing.

Abstract

To investigate the extent and practice of home-based treatment for patients with hematologic malignancies in Denmark.

This nationwide exploratory study was conducted at all Danish hematologic departments (n = 9). Each site received an online questionnaire for the collection of data on the type of therapy administered as home-based treatment, the specific treatments with details on target populations, patient criteria, implementation status, and practice for clinical management.

Six types of therapy were offered as home-based treatments across the Danish hematologic departments: chemotherapy, immunoglobulin, immunotherapy, hydration therapy, antibiotics, and parenteral nutrition. In total, 17 treatments were offered, with the majority being provided to patients with multiple myeloma. Immunoglobulin and antibiotics were most often provided at home. Variations were identified regarding patient criteria for receiving home-based treatment, including personal resources and social networks, use of intravenous accesses and infusion pumps, and timing of initiation of home-based treatment.

There is variation in the implementation of home-based treatment for patients with hematologic malignancies in Denmark, including different criteria and practices. To fully realize the benefits of home-based treatment, it is imperative to address access disparities, standardize practices, and enhance support for patients and caregivers. Continued research, collaboration, and policy development are essential to ensure that all patients have equitable access to high-quality home-based treatment options.

Figures